[Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004065
Original Title: Sacituzumab Govitecan (Mammakarzinom) - Nutzenbewertung gemäß § 35a SGB V
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Breast Neoplasms
  • Triple Negative Breast Neoplasms
  • Camptothecin
  • Immunoconjugates
  • Antibodies, Monoclonal, Humanized
  • Sacituzumab Govitecan
  • Triple Negative Breast Neoplasms
  • Benefit Assessment
  • NCT02574455
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.